M&A Deal Summary |
|
|---|---|
| Date | 2013-08-26 |
| Target | Amplimmune |
| Sector | Life Science |
| Buyer(s) | MedImmune |
| Deal Type | Add-on Acquisition |
| Deal Value | 500M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1988 |
| Sector | Medical Products |
| Employees | 2,000 |
MedImmune strives to provide better medicines to patients, new medical options for physicians, rewarding careers to employees, and increased value to shareholders. Dedicated to advancing science and medicine to help people live better lives, the company is focused on the areas of infectious diseases, cancer and inflammatory diseases. With approximately 2,000 employees worldwide, MedImmune is headquartered in Maryland.
| DEAL STATS | # |
|---|---|
| Overall | 4 of 6 |
| Sector (Life Science) | 4 of 6 |
| Type (Add-on Acquisition) | 4 of 5 |
| State (Maryland) | 2 of 2 |
| Country (United States) | 4 of 4 |
| Year (2013) | 2 of 4 |
| Size (of disclosed) | 1 of 3 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-04-03 |
AlphaCore Pharma
Ann Arbor, Michigan, United States AlphaCore Pharma, an Ann Arbor, Michigan-based biotechnology company focused on the development of ACP-501, a recombinant human lecithin-cholesterol acyltransferase (LCAT) enzyme. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-10-15 |
Spirogen
London, United Kingdom The Spirogen group was founded in 2001 as a spin-out from several institutions including University College London and with partial funding by Cancer Research UK. It is majority owned by Auven Therapeutics. It has developed a novel class of highly potent cytotoxic warheads based on its proprietary pyrrolobenzodiazepines (PBDs), DNA minor groove binding agents, which bind and cross-link specific sites of DNA of the cancer cell. |
Buy | $240M |
